Short communication

In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine

Jessica D. Church, Anthony Mwatha, Danstan S Bagenda, Saad B. Omer, Deborah Donnell, Philippa Musoke, Clemensia Nakabiito, Chineta Eure, Paul Bakaki, Flavia Matovu, Michael C. Thigpen, Laura A. Guay, Michelle McConnell, Mary Glenn Fowler, J. Brooks Jackson, Susan H. Eshleman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis. We combined results from four clinical trials to analyze predictors of NVP resistance in sdNVP-exposed Ugandan infants. Samples were tested with the ViroSeq HIV Genotyping System and a sensitive point mutation assay (LigAmp, for detection of K103N, Y181C, and G190A). NVP resistance was detected at 6-8 weeks in 36 (45.0%) of 80 infants using ViroSeq and 33 (45.8%) of 72 infants using LigAmp. NVP resistance was more frequent among infants who were infected in utero than among infants who were diagnosed with HIV infection after birth by 6-8 weeks of age. Detection of NVP resistance at 6-8 weeks was not associated with HIV subtype (A vs. D), pre-NVP maternal viral load or CD4 cell count, infant viral load at 6-8 weeks, or infant sex. NVP resistance was still detected in some infants 6-12 months after sdNVP exposure. In this study, in utero HIV infection was the only factor associated with detection of NVP resistance in infants 6-8 weeks after sdNVP exposure.

Original languageEnglish (US)
Pages (from-to)673-677
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Nevirapine
HIV Infections
Communication
HIV
Viral Load
Mothers
CD4 Lymphocyte Count
Point Mutation
Clinical Trials
Parturition

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Short communication : In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. / Church, Jessica D.; Mwatha, Anthony; Bagenda, Danstan S; Omer, Saad B.; Donnell, Deborah; Musoke, Philippa; Nakabiito, Clemensia; Eure, Chineta; Bakaki, Paul; Matovu, Flavia; Thigpen, Michael C.; Guay, Laura A.; McConnell, Michelle; Fowler, Mary Glenn; Jackson, J. Brooks; Eshleman, Susan H.

In: AIDS Research and Human Retroviruses, Vol. 25, No. 7, 01.07.2009, p. 673-677.

Research output: Contribution to journalArticle

Church, JD, Mwatha, A, Bagenda, DS, Omer, SB, Donnell, D, Musoke, P, Nakabiito, C, Eure, C, Bakaki, P, Matovu, F, Thigpen, MC, Guay, LA, McConnell, M, Fowler, MG, Jackson, JB & Eshleman, SH 2009, 'Short communication: In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine', AIDS Research and Human Retroviruses, vol. 25, no. 7, pp. 673-677. https://doi.org/10.1089/aid.2009.0003
Church, Jessica D. ; Mwatha, Anthony ; Bagenda, Danstan S ; Omer, Saad B. ; Donnell, Deborah ; Musoke, Philippa ; Nakabiito, Clemensia ; Eure, Chineta ; Bakaki, Paul ; Matovu, Flavia ; Thigpen, Michael C. ; Guay, Laura A. ; McConnell, Michelle ; Fowler, Mary Glenn ; Jackson, J. Brooks ; Eshleman, Susan H. / Short communication : In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. In: AIDS Research and Human Retroviruses. 2009 ; Vol. 25, No. 7. pp. 673-677.
@article{cf7d750310d849a6a2769e9b3e68f15b,
title = "Short communication: In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine",
abstract = "Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis. We combined results from four clinical trials to analyze predictors of NVP resistance in sdNVP-exposed Ugandan infants. Samples were tested with the ViroSeq HIV Genotyping System and a sensitive point mutation assay (LigAmp, for detection of K103N, Y181C, and G190A). NVP resistance was detected at 6-8 weeks in 36 (45.0{\%}) of 80 infants using ViroSeq and 33 (45.8{\%}) of 72 infants using LigAmp. NVP resistance was more frequent among infants who were infected in utero than among infants who were diagnosed with HIV infection after birth by 6-8 weeks of age. Detection of NVP resistance at 6-8 weeks was not associated with HIV subtype (A vs. D), pre-NVP maternal viral load or CD4 cell count, infant viral load at 6-8 weeks, or infant sex. NVP resistance was still detected in some infants 6-12 months after sdNVP exposure. In this study, in utero HIV infection was the only factor associated with detection of NVP resistance in infants 6-8 weeks after sdNVP exposure.",
author = "Church, {Jessica D.} and Anthony Mwatha and Bagenda, {Danstan S} and Omer, {Saad B.} and Deborah Donnell and Philippa Musoke and Clemensia Nakabiito and Chineta Eure and Paul Bakaki and Flavia Matovu and Thigpen, {Michael C.} and Guay, {Laura A.} and Michelle McConnell and Fowler, {Mary Glenn} and Jackson, {J. Brooks} and Eshleman, {Susan H.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1089/aid.2009.0003",
language = "English (US)",
volume = "25",
pages = "673--677",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Short communication

T2 - In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine

AU - Church, Jessica D.

AU - Mwatha, Anthony

AU - Bagenda, Danstan S

AU - Omer, Saad B.

AU - Donnell, Deborah

AU - Musoke, Philippa

AU - Nakabiito, Clemensia

AU - Eure, Chineta

AU - Bakaki, Paul

AU - Matovu, Flavia

AU - Thigpen, Michael C.

AU - Guay, Laura A.

AU - McConnell, Michelle

AU - Fowler, Mary Glenn

AU - Jackson, J. Brooks

AU - Eshleman, Susan H.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis. We combined results from four clinical trials to analyze predictors of NVP resistance in sdNVP-exposed Ugandan infants. Samples were tested with the ViroSeq HIV Genotyping System and a sensitive point mutation assay (LigAmp, for detection of K103N, Y181C, and G190A). NVP resistance was detected at 6-8 weeks in 36 (45.0%) of 80 infants using ViroSeq and 33 (45.8%) of 72 infants using LigAmp. NVP resistance was more frequent among infants who were infected in utero than among infants who were diagnosed with HIV infection after birth by 6-8 weeks of age. Detection of NVP resistance at 6-8 weeks was not associated with HIV subtype (A vs. D), pre-NVP maternal viral load or CD4 cell count, infant viral load at 6-8 weeks, or infant sex. NVP resistance was still detected in some infants 6-12 months after sdNVP exposure. In this study, in utero HIV infection was the only factor associated with detection of NVP resistance in infants 6-8 weeks after sdNVP exposure.

AB - Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis. We combined results from four clinical trials to analyze predictors of NVP resistance in sdNVP-exposed Ugandan infants. Samples were tested with the ViroSeq HIV Genotyping System and a sensitive point mutation assay (LigAmp, for detection of K103N, Y181C, and G190A). NVP resistance was detected at 6-8 weeks in 36 (45.0%) of 80 infants using ViroSeq and 33 (45.8%) of 72 infants using LigAmp. NVP resistance was more frequent among infants who were infected in utero than among infants who were diagnosed with HIV infection after birth by 6-8 weeks of age. Detection of NVP resistance at 6-8 weeks was not associated with HIV subtype (A vs. D), pre-NVP maternal viral load or CD4 cell count, infant viral load at 6-8 weeks, or infant sex. NVP resistance was still detected in some infants 6-12 months after sdNVP exposure. In this study, in utero HIV infection was the only factor associated with detection of NVP resistance in infants 6-8 weeks after sdNVP exposure.

UR - http://www.scopus.com/inward/record.url?scp=70349227287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349227287&partnerID=8YFLogxK

U2 - 10.1089/aid.2009.0003

DO - 10.1089/aid.2009.0003

M3 - Article

VL - 25

SP - 673

EP - 677

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 7

ER -